Literature DB >> 23501443

Increased sensitivity of SPR assays in plasma through efficient parallel assay optimization.

Anna Moberg1, Anna Lager, Markku D Hämäläinen, Tanja Jarhede.   

Abstract

The sensitivity of biosensor assays in complex media such as plasma or serum is often limited by non-specific binding. The degree of binding often varies between individuals and therefore a large number of different plasma samples have to be used during assay development. Some surface plasmon resonance (SPR) biosensors allow for parallel screening of several running buffer compositions, with a number of different immobilization levels for each buffer. These technical possibilities combined with statistical design of experiments (DoE) enable efficient parallel optimization of multiple assay conditions. In this paper we outline how to increase the sensitivity in SPR-based assays by minimizing background binding and variability from negative control plasma while retaining high signals from positive samples. To mimic immunogenicity studies of biotherapeutics we have used a model assay with anti-rituximab as an anti-drug antibody to be detected in plasma by binding to immobilized rituximab. Immobilization level and sodium chloride concentration were found to be the most important factors to optimize. There were also a number of significant interaction effects and strong non-linearites between the buffer composition/immobilization level and the assay performance, which necessitated DoE based optimization strategies. The applicability of the optimized conditions was verified with several assays (anti-erythropoietin, omalizumab, anti-IgE and anti-myoglobin) in spiked plasma samples resulting in detection levels in the range of 80-170 ng ml(-1). The buffer conditions presented in this paper can be used for other immunogenicity assays on biosensor platforms or as a good starting point for further assay development for new immunogenicity assays.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23501443     DOI: 10.1016/j.jpba.2013.02.018

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  sMAdCAM: IL-6 Ratio Influences Disease Progression and Anti-Viral Responses in SARS-CoV-2 Infection.

Authors:  Dhanashree Jagtap; Vikrant M Bhor; Shilpa Bhowmick; Nandini Kasarpalkar; Pooja Sagvekar; Bhalchandra Kulkarni; Manish Pathak; Nirjhar Chatterjee; Pranam Dolas; Harsha Palav; Snehal Kaginkar; Sharad Bhagat; Itti Munshi; Swapneil Parikh; Sachee Agrawal; Chandrakant Pawar; Mala Kaneria; Smita D Mahale; Jayanthi Shastri; Vainav Patel
Journal:  Front Immunol       Date:  2021-06-14       Impact factor: 7.561

2.  Plastic antibodies tailored on quantum dots for an optical detection of myoglobin down to the femtomolar range.

Authors:  Ana Margarida Piloto; David S M Ribeiro; S Sofia M Rodrigues; Catarina Santos; João L M Santos; M Goreti F Sales
Journal:  Sci Rep       Date:  2018-03-21       Impact factor: 4.379

3.  Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor.

Authors:  Rosa Helena Bustos; Carlos Zapata; Efraín Esteban; Julio-César García; Edwin Jáuregui; Diego Jaimes
Journal:  Sensors (Basel)       Date:  2018-02-26       Impact factor: 3.576

4.  An optical biosensor assay for rapid dual detection of Botulinum neurotoxins A and E.

Authors:  Christian Lévêque; Géraldine Ferracci; Yves Maulet; Christelle Mazuet; Michel R Popoff; Marie-Pierre Blanchard; Michael Seagar; Oussama El Far
Journal:  Sci Rep       Date:  2015-12-09       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.